SCHEMBL4625813

SCHEMBL4625813

CC(C)(C)O[Si](Oc1ccc(C(O)(c2ccccc2)c2ccccc2)cc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.37
CYP3A4 P08684 3/20 0.36
CYP3A5 P20815 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
ACSS2 Q9NR19 5/20 0.34
NR1H2 P55055 2/20 0.34
NR1H3 Q13133 2/20 0.34
AHR P35869 1/20 0.34
ALDH1A1 P00352 2/20 0.33
ALOX15 P16050 1/20 0.33
MAPT P10636 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KMT2A Q03164 1/20 0.33
ESR1 P03372 2/20 0.33
ESR2 Q92731 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4625906 1.00 CYP19A1 (0.37) CYP19A1CYP3A4CYP3A5SMN1; SMN2ACSS2
SCHEMBL4625644 0.98 NR1H2 (0.35) CYP19A1CYP3A4CYP3A5SMN1; SMN2ACSS2
SCHEMBL4624733 0.94 AHR (0.42) CYP19A1SMN1; SMN2ACSS2AHRKMT2A
SCHEMBL4626920 0.93 AHR (0.43) CYP19A1SMN1; SMN2ACSS2AHRALDH1A1
SCHEMBL4624707 0.93 AHR (0.43) CYP19A1SMN1; SMN2ACSS2AHRALDH1A1
SCHEMBL4626091 0.80 ALDH1A1 (0.35) ALDH1A1MAPTTDP1KMT2A
SCHEMBL4625876 0.79 ELANE (0.49)
SCHEMBL4627027 0.78 KIF11 (0.41) SMN1; SMN2AHRALDH1A1ALOX15TDP1
SCHEMBL4627743 0.78 ELANE (0.51) ALDH1A1TDP1
SCHEMBL14230792 0.74 MAPT (0.41) CYP19A1CYP3A4CYP3A5NR1H2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401851-B8 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS FEBIT HOLDING GMBH (DE) 2008-09-10 EP disclosed
EP-1401851-B1 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS FEBIT BIOTECH GMBH (DE) 2008-07-02 EP disclosed
US-7355036-B2 Two-stage protective groups for the synthesis of biopolymers FEBIT AG (DE) 2008-04-08 US disclosed
US-20040197851-A1 Two-stage protective groups for the synthesis of biopolymers MR. CHRISTOPHER SEAGON, ESQ. (DE) 2004-10-07 US disclosed
EP-1401851-A1 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS Febit AG (DE) 2004-03-31 EP disclosed
WO-2003004510-A1 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS FEBIT AG (DE) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197851-A1 Two-stage protective groups for the synthesis of biopolymers CTRB2, OGG1, CPB2 CYP19A1 3284/4885CYP3A4 2862/4885CYP3A5 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.